The melanoma differentiation-associated gene-7 (mda-7) was identified by virtue of its enhanced expression in human melanoma cells induced into terminal differentiation. Enforced expression of mda-7 in human cancer cell lines of diverse origins results in the suppression of growth and induction of apoptosis. We have shown that adenoviral-mediated mda-7 (Ad-mda7) radiosensitizes non-small-cell lung cancer (NSCLC) cells by enhancing the apoptotic pathway. To identify the mechanism of this radiosensitization, we examined the level of proteins involved in the nonhomologous end-joining (NHEJ) pathway of DNA double-strand break (DSB) repair. Western blot analysis indicated that the expression of NHEJ pathway components Ku70, XRCC4, and DNA ligase IV was downregulated in NSCLC cells -A549 with Ad-mda7 treatment. No such change was observed in normal human CCD16 fibroblasts previously shown not to be radiosensitized by Ad-mda7. The biological significance of these changes of expression of proteins critical for repair of radiation-induced DSBs was confirmed via the analysis of DSB rejoining kinetics using pulsed field gel electrophoresis and assessment of host cell reactivation capacity following Ad-mda7 treatment. Based on these results, we hypothesize that Ad-mda7 sensitizes NSCLC cells to ionizing radiation by suppressing the activity of NHEJ, a pathway essential for repair of radiation-induced DSBs.
Introduction
Lung cancer is the leading cause of death among all malignancies in the Western world. In particular, nonsmall-cell lung cancer (NSCLC) accounts for 75-80% of all lung cancers (Parker et al., 1997) . The only curative treatment currently available for NSCLC is surgical resection. Patients with nonresectable tumors typically undergo palliative chemotherapy or radiotherapy, but the expected survival rate in patients with stage III B-IV NSCLC is still o20% at 2 years. Thus, alternate treatments for patients with advanced NSCLC are sorely needed. This situation has stimulated investigation of novel strategies, including those involving gene therapy.
Although a number of gene therapy strategies for NSCLC are currently being studied, adenoviralmediated expression of the melanoma differentiationassociated (mda-7) gene (Ad-mda7) may be particularly promising. Using a modified subtraction hybridization scheme, Jiang et al. (1995) isolated mda-7 from human melanoma cells that had been induced into terminal differentiation. The demonstration in this initial report that mda-7 is expressed in normal melanocytes during the early stages of melanoma but lost during melanoma progression suggested that mda-7 is a novel tumor suppressor gene. In subsequent investigations carried out by this group, induction of growth suppression and apoptosis was apparent in cancer cells from diverse origins, such as those in the breast, lung, colon, cervix, and prostate, when mda-7 was overexpressed using a replication-incompetent adenovirus (Ad-mda7) (Jiang et al., 1996) . These effects were not evident in normal human cells. These early reports have prompted more detailed evaluations of the use of Ad-mda7 as a gene therapy strategy for cancer.
In recent investigations, Ad-mda7 has been shown to inhibit the growth of NSCLC cells both in vitro and in vivo (Saeki et al., 2000; Saeki et al., 2002) . Furthermore, in the anticipation that Ad-mda7 therapy may be combined with radiotherapy, we demonstrated that Ad-mda7 sensitized NSCLC cell lines to ionizing radiation by enhancing the apoptosis pathway . It was also recently reported that both Admda7 and purified MDA-7 protein sensitize malignant glioma cells to ionizing radiation (Su et al., 2003) . The mda-7 gene has been mapped to chromosome 1q32, where an interleukin 10-related gene cluster containing four genes , and mda-7) is also located (Blumberg et al., 2001; Mhashilkar et al., 2001 ).
MDA-7 protein displays 22% amino-acid identity with interleukin 10. The analysis of the expression profile of mda-7 in different human tissues has shown that expression is restricted to those tissues associated with the immune system, such as the spleen, the thymus, and peripheral blood leukocytes, suggesting that the mda-7 gene product has cytokine-like properties (Huang et al., 2001) . Based on these observations, mda-7 was classified as interleukin-24 with the approval of the Human Genome Organization Gene Nomenclature Committee.
In spite of the identification of the protein product of the mda-7 gene as a cytokine, the mechanisms by which Ad-mda7 produces an antitumor effect and radiosensitizes tumor cells are not understood. Therefore, the purpose of the present study was to elucidate the mechanisms underlying the radiosensitizing effect of Ad-mda7 in NSCLC cells. Based on the fact that the radiosensitivity of cells is primarily governed by their capacity for DNA repair, we examined the relationship between ectopic expression of mda-7 and the nonhomologous end-joining (NHEJ) pathway for repair of radiation-induced DNA double-strand breaks (DSBs).
Results

Ad-mda7 suppresses the expression of proteins involved in DNA repair in NSCLC cells but not in normal fibroblasts
In our previous study, we reported that Ad-mda7 radiosensitized NSCLC cells but not normal fibroblasts and that this correlated with the ability of this vector to induce activation of the c-Jun transcription factor in NSCLC cells but not fibroblasts . Thus, it was of interest to test for changes in the expression of genes that are important in governing radiosensitivity, such as those in DNA repair pathways.
In mammalian cells, NHEJ is the predominant pathway for repairing DSBs induced by exposure to ionizing radiation. To determine whether Ad-mda7 affects the level of expression of proteins involved in the NHEJ pathway, we performed Western blot analysis on nuclear protein extracts. As shown in Figure 1a , the level of expression of Ku70, XRCC4, and DNA ligase IV protein was reduced by Ad-mda7 treatment in the NSCLC cell line, A549. On the other hand, there was no reduction in the expression of any of these proteins in the normal human lung fibroblast CCD16 cells when treated in an identical manner (Figure 1c ). The effects in the NSCLC cells appeared to be specific to Ad-mda7, as a control vector, adenovirus-mediated luciferase (AdLuc), did not affect the expression of these proteins in either cell line (Figure 1b and d) .
Ad-mda7 reduces the expression of DNA repair gene mRNA in A549 cells
To determine whether the suppressed protein levels seen in Figure 1a reflected reduced transcription of the genes that code for these proteins, we carried out an RNase protection assay for the genes of interest. The results showed that the mRNA levels for several DNA repair genes were lower in A549 cells treated with Ad-mda7 than in untreated controls (Figure 2 ). For some genes, Figure 1 Western blot analysis of DNA-PKcs, Ku70, Ku86, XRCC4, and DNA ligase IV protein expression levels in (a, b) A549 and (c, d) CCD16 cells. Cells were pretreated with Ad-mda7 (a, c) or Ad-Luc (b, d) as a control vector and analysed on day 1 (D1), day 2 (D2), or day 3 (D3) after transfection. The vector dose was 1000 vp/cell for A549 cells and 1500 vp/cell for CCD16 cells. The vector doses were based on equal levels of infectivity Radiosensitizing effects of Ad-mda7
T Nishikawa et al the control vector, Ad-Luc, also affected transcription. However, transcription for several of the genes of interest -Ku70, Lig4, XRCC4, and DNA-PK -was affected to a greater degree by Ad-mda7 than by Ad-Luc.
DNA DSB repair after irradiation is suppressed by Ad-mda7 transfection
Although the suppressed expression of genes whose protein products are crucial for repairing radiationinduced DSBs as illustrated above is consistent with the radiosensitizing effects of Ad-mda7, it was necessary to confirm that repair of these lesions was actually compromised following this treatment. Thus, the total DSB induction and rejoining following irradiation was examined using pulsed field gel electrophoresis (PFGE) to determine whether Ad-mda7 transfection affected DSB rejoining kinetics in A549 cells. An autoradiogram of a typical PFGE gel is shown in Figure 3a . As seen in this autoradiogram, a substantial amount of fragmented DNA migrated out of the plugs and into the lanes following delivery of a dose of 40 Gy when examined at time point 0. This effect was similar for Ad-mda7-treated cells and controls, indicating that Ad-mda7 treatment does not enhance the induction of DSBs by radiation. However, as a function of time, the proportion of DNA in the lane was reduced as the DSBs were rejoined; this appeared to be a slower process in the Admda7-treated cells than in the controls. A number of gels like that in Figure 3a were quantified, and the average values were plotted to evaluate the kinetics of DSB repair following the different treatments ( Figure 3b ). Although the overall kinetics of repair were similar in the different groups, it appeared that pretreatment with Ad-mda7 resulted in a higher level of residual unrejoined lesions at 1440 min (24 h) compared with untreated controls or cells pretreated with Ad-Luc. These differences were statistically significant at the P ¼ 0.05 level for Ad-mda7 versus Ad-Luc at 120, 240, and 1440 min. At 1440 min Admda7 was also different from the control, P ¼ 0.011.
Host cell reactivation (HCR) is suppressed by Ad-mda7 in A549 cells but not in CCD16 cells
Strictly speaking, the PFGE assay for DSB repair, when used as described above, actually measures the total DSB rejoining, which includes the inappropriate rejoining of broken DNA fragments such as those that lead to chromosomal translocations. Furthermore, since it does not detect misrepaired lesions that result in deletions, it overestimates the amount of repair that contributes to cell survival. Thus, to investigate the fidelity and total capacity for DNA repair, we used the HCR assay as a further test of Ad-mda7's ability to suppress the DNA repair pathways that govern radiosensitivity. Gamma-irradiated adenoviral-mediated b-galactosidase Figure 2 RNase protection assay used to examine the mRNA level of DNA repair genes. A549 cells were transfected with 1000 vp/cell of Ad-mda7 or Ad-Luc. At 2 days after transfection, the cells were harvested, and total RNA was extracted. The relative values shown were determined via phosphorimaging using the ImageQuant software program. Two housekeeping genes, L32 and GAPDH, were used for normalization (Figure 4a ). These differences were statistically significant at the P ¼ 0.05 level for Ad-mda7 versus control and Ad-mda7 versus Ad-Luc for all doses except 2000 Gy where Ad-mda7 versus Ad-Luc was not significant at this level, P ¼ 0.051. In contrast, significant suppression of HCR was not observed in CCD16 cells following pretreatment with Ad-mda7 (Figure 4b ). To confirm that our HCR assay was sufficiently sensitive to detect known defects in DNA repair, we tested the assay on the human glioblastoma cell lines MO59 K and MO59J, which are proficient and deficient in DNA-dependent protein kinase (DNA-PK), respectively. HCR was significantly reduced in MO59J cells when compared with that in MO59K cells (Figure 4c ) by factors approaching 50%. These differences were statistically significant at the Po0.05 level for MO59K versus MO59J at all doses except 4000 Gy where P ¼ 0.06. DNA-PK, which comprises the Ku70/Ku80 heterodimer and the catalytic subunit DNA-PKcs, is required for the NHEJ pathway of DSB repair. Cells lacking DNA-PK activity because of defects in DNA-PK components, such as M059J cells, have shown hypersensitivity to ionizing radiation and compromised DSB rejoining kinetics (Allalunis-Turner et al., 1993; Lees-Miller et al., 1995) .
Discussion
A DNA DSB is a type of DNA damage induced by a variety of genotoxic agents, especially ionizing radiation. DSBs are highly cytotoxic lesions that disrupt the genomic integrity of a cell, leading to chromosomal aberrations such as translocations and deletions. Thus, prompt, efficient repair of DSBs is essential for maintaining the viability and genomic stability of mammalian cells. Enhancement of the ability of tumor cells to repair DSBs may be a major cause of resistance to ionizing radiation. Thus, strategies for suppressing DNA repair capacity may be advantageous in treating cancer with radiation. In eucaryotes, DSB repair involves two principal but distinct pathways: homologous recombination and NHEJ (Haber, 2000; Jeggo, 1998; Khanna and Jackson, 2001) . NHEJ is the predominant mechanism by which mammalian cells repair DSBs caused by exposure to ionizing radiation (at least those DSBs that potentially contribute to lethality) (Olive, 1998) . This prompted us to focus on the NHEJ pathway to explain the radiosensitizing effect of Ad-mda7.
Genetic and biochemical studies have revealed at least five proteins that have essential roles in the repair of DSBs through the NHEJ pathway (Critchlow and Jackson, 1998; Hopfner et al., 2002; Junop et al., 2000; Lieber, 1999; Sibanda et al., 2001; Walker et al., 2001) . Three of these proteins are components of a large complex known as DNA-PK. This complex consists of a tightly associated 70-/86-kDa heterodimer known as Ku 
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T Nishikawa et al and a 465-kDa catalytic subunit (DNA-PKcs). The fourth gene product is XRCC4, a 38-kDa nuclear phosphoprotein, which is tightly associated with the fifth gene product, DNA ligase IV, resulting in stabilization of the protein and stimulation of its ligase activity (Bryans et al., 1999; Grawunder et al., 1997) .
In the present study, we first investigated the level of expression of the proteins involved in the NHEJ pathway using Western blot analysis. The data indicated that the expression of Ku70, XRCC4, and DNA ligase IV was downregulated in A549 cells pretreated with Admda7 compared with that in mock-and Ad-Luc-treated cells. However, no such changes were observed in CCD16 cells treated with Ad-mda7 (Figure 1 ). Using the RNase protection assay, we subsequently demonstrated decreased levels of mRNA of the genes that code for these proteins in A549 cells pretreated with Admda7, suggesting that Ad-mda7 alters the transcription of these genes (Figure 2) .
In mammalian cells, deficiencies in any one of these genes lead to similar phenotypes, including growth defects, premature senescence, sensitivity to ionizing radiation, and inability to support V(D)J recombination (Gu et al., 1997a; Lees-Miller et al., 1995; Riballo et al., 1999; Sado et al., 2001; Smith and Jackson, 1999) . In comparison with these studies using mice or cells in which the gene in question had been deleted or knocked out, Ad-mda7 only partially suppresses gene/protein expression, raising the question of whether this partial suppression is sufficient to affect DNA repair capacity. Therefore, we tested the ability of Ad-mda7 to affect this capacity using two independent methods. First, we used PFGE to examine DSB rejoining. PFGE results demonstrated a moderate reduction in DSB rejoining following Ad-mda7 transfection (Figure 3) . However, this procedure may underestimate the degree of functional impairment of repair, as it detects misrepaired breaks as being rejoined. Thus, we also used the HCR assay using gamma-irradiated Ad-b-gal as the reporter vector to assess the fidelity of DSB repair in this context (Figure 4) . HCR was suppressed by the pretreatment of A549 cells with Admda7, but this suppression was not observed in the normal fibroblast line CCD16. In a side-by-side comparison with the degree of HCR of suppression seen in the DNA-PK-deficient cell line M059J relative to its wild-type control line, it appeared that Ad-mda7 produced a comparable but not equal level of HCR suppression.
On the other hand, it should be noted that the radiosensitizing effect of Ad-mda7 was not equivalent to that due to a complete deficiency in DNA-PK because the surviving fraction at 2 Gy (SF 2 ) value for the M059J cells is reduced to 0.02 compared with the M059K cell value of 0.64 (Allalunis-Turner et al., 1993) , whereas Ad-mda7 pretreatment reduced the SF 2 value for the control A549 cells from 0.70 to 0.39 . It would appear, therefore, that the overall suppression of HCR seen after Ad-mda7 is due to a combination of factors that may include a partial downregulated expression of several components of the NHEJ pathway and the contribution of these to a radiosensitizing effect is complex. Similar relationships have been uncovered in other recent reports where the goal was to induce radiosensitivity in tumor cells using therapeutic strategies that targeted specific components of the NHEJ pathway. Omori et al. (2002) evaluated an antisense construct to Ku70 and demonstrated a substantial suppression of Ku70 protein but only a modest radiosensitizing effect. In another study, using adenoviral-mediated, heat-activated antisense Ku70, the SF 2 values were reduced from about 0.80 to 0.50 in the context of an almost complete suppression of Ku70 protein expression (Li et al., 2003) . Small interfering RNA molecules (siRNAs) targeting DNA-PKcs have also been explored in two reports. Both reports (Collis et al., 2003; Peng et al., 2002) report modest radiosensitizing effects in cell systems where protein levels of DNA-PKcs were suppressed to varying degrees. Since none of these studies examined the effects of the treatments on DNA repair, a direct comparison with our study is not possible. However, the radiosensitizing effect of Ad-mda7 that we have reported previously and the degree of suppression of key components of the NHEJ pathway reported here are comparable to what was reported for these other strategies. Thus, it appears reasonable to propose that the radiosensitizing effect of Ad-mda7 is due to the observed suppressed expression of NHEJ components and capacity for HCR.
The differences reported here between the NSCLC cell line A549 and the normal fibroblast line CCD16 with regard to the ability of Ad-mda7 to suppress DNA repair are also consistent with our previous study showing that Ad-mda7 radiosensitizes A549 cells but not CCD16 fibroblasts . In that study, we also showed that Ad-mda7 treatment activated the stress-activated protein kinase c-Jun N-terminal kinase (JNK). This effect, which does not take place in normal cells, may ultimately lead to the changes in gene expression responsible for radiosensitization. It appears that Ad-mda7 activates several signal transduction pathways in NSCLC cells. In addition to our previous observation related to JNK activation, other investigators have reported that Ad-mda7 may also activate p38 (Sarkar et al., 2002) and PKR (Pataer et al., 2002) . It will ultimately be important to determine which of these or other signaling pathways activated in Ad-mda7-infected cells is responsible for the downregulation of components of NHEJ.
In conclusion, the results presented here suggest that the radiosensitizing effects of Ad-mda7 are at least partly mediated by a suppression of components of the NHEJ pathway leading to a suppressed capacity for repair of radiation-induced DSBs. These observations support the continued development of the combination of gene therapy with Ad-mda7 and radiation for the treatment of NSCLC and other cancers.
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Materials and methods
Cell culture
The human NSCLC cell line A549, normal human lung fibroblast cell line CCD16, and human glioma cell lines MO59J and MO59K were obtained from the American Type Culture Collection (Manassass, VA, USA). All of the cell lines were maintained as specified by the American Type Culture Collection.
Adenoviral vectors and gene delivery
Ad-mda7, Ad-Luc, and Ad-b-gal were all obtained from Introgen Therapeutics, Inc. (Houston, TX, USA). Ad-Luc was used as a control vector and Ad-b-gal was used as a reporter vector. The vectors were tested for the presence of and determined to be free of replication-competent adenovirus and mycoplasma. At 48 h after plating, cells were incubated for 1 h with a purified vector in 1 ml of medium without serum. After incubation, fresh medium supplemented with 10% fetal bovine serum was added to each flask. Serum-free medium was used in a protocol that was identical except for the inclusion of a vector for mock transfection. Cell numbers for multiplicity of infection calculations were determined by counting the cells in an untreated flask.
Radiation
Cells were irradiated with a 137 Cs unit (3.7 Gy/min) at room temperature in T25 flasks. Irradiation was performed 48 h after vector treatment.
Nuclear protein extract
Cells were rinsed twice with ice-cold phosphate-buffered saline, harvested with a cell scraper, and centrifuged at 500 g for 10 min at 41C. The cell pellet was then resuspended in 400 ml of cold lysis buffer (10.0 mM HEPES, pH 7.9, 10.0 mM KCl, 0.1 mM ethylenediaminetetraacetic acid, 0.1 mM egtazic acid, 1.0 mM dithiothreitol, 2.0 mg/ml leupeptin, 2.0 mg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride) and incubated on ice for 10 min; afterwards, 12.5 ml of 10% NP-40 was added, and the mixture was vortexed for 5 s. Next, the lysate was centrifuged at 500 g for 5 min at 41C and the supernatant was removed and stored as a cytosolic extract. The pellet was resuspended in 30 ml of extraction buffer (20.0 mM HEPES, pH 7.9, 400.0 mM NaCl, 1.0 mM ethylenediaminetetraacetic acid, 1.0 mM egtazic acid, 1.0 mM dithiothreitol, 2.0 mg/ml leupeptin, 2.0 mg/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride), mixed thoroughly, and incubated on ice for 30 min. The pellet was then vortexed every 10 min. After 30 min, the extract was centrifuged for 10 min at maximum speed in a microcentrifuge. The supernatant was designated as a nuclear extract, aliquoted, and stored at À701C. The amount of nuclear protein obtained was determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Richmond, CA, USA) in accordance with the manufacture's instructions and using bovine serum albumin as a protein standard.
Antibodies
Rabbit polyclonal antibodies against DNA-PKcs and XRCC4 were purchased from GeneTex (San Antonio, TX, USA). Goat polyclonal antibodies against Ku70 and b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A mouse monoclonal antibody against Ku86, clone Ku15, was purchased from Sigma-Aldrich (St Louis, MO, USA). A rabbit polyclonal antibody against DNA ligase IV was purchased from Serotec (Raleigh, NC, USA).
Western blot analysis
Equal amounts of nuclear protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (8-12% polyacrylamide with a 4% stacking gel) and then transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). Nonfat dry milk, 5%, in TBS-T (TBS with 0.05% Tween-20) was used as a blocking solution, while TBS-T alone was used as a washing buffer. The membranes were treated with primary antibodies in a blocking solution at 41C overnight and with secondary antibodies in a blocking solution at room temperature for 1 h. The results were visualized with enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA) according to the manufacturer's protocol.
RNase protection assay
Cells were transfected with either Ad-mda7 or Ad-Luc. After 48 h of incubation, RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). Probes were labeled with [ 32 P]UTP and hybridized with the isolated RNA. The probe set used was hDSBR-2 (Pharmingen, San Diego, CA, USA). The housekeeping genes, L32 and GAPDH, were used for sample normalization. After RNase digestion, the protected fragments were separated via polyacrylamide gel electrophoresis. All of the steps were performed according to the manufacturer's recommendations.
DNA DSB repair assay
Assay of DNA DSB repair activity following exposure to ionizing radiation was performed as described previously (Kurimasa et al., 1999; Story et al., 1994) . Briefly, 48 h after vector treatment, cells were irradiated on ice using a 137 Cs unit (3.5 Gy/min), receiving a cumulative dose of 40 Gy. Immediately following irradiation, the cold medium was replaced with medium that had been warmed to 371C, and the cells were placed in a 371C tissue culture incubator for the appropriate time (0-1440 min) to allow the DSBs to be repaired. Cells were then trypsinized on ice, washed, embedded in agarose plugs, lysed, and digested with proteinase K. The DNA was separated using contour-clamped homogeneous electric field PFGE (CHEF-DR III system, Bio-Rad Laboratories) at 1.5 V/cm for 20 h at 251C in 0.5 Â TBE buffer. The gel was transferred to a nylon membrane for 3 days at room temperature. The membrane was then hybridized with a 32 Plabeled human Alu þ probe for 18 h at 451C. The fraction of activity released from the plug into the lane was determined using a storage phosphorimaging system with the ImageQuant software program (Molecular Dynamics, Sunnyvale, CA, USA).
HCR
A modified version of the HCR assay was used to assess DNA repair capacity (Eady et al., 1992; McDonald et al., 1996; Rainbow, 1974; Rainbow and Mak, 1972) . Briefly, cells were seeded in a six-well plate and pretreated with Ad-mda7, Ad-Luc, or mock as described above. Cells were then transfected with nonirradiated or irradiated Ad-b-gal 48 h after pretreatment. Ad-b-gal was irradiated using a high-dose rate 137 Cs unit (34.3 Gy/min) at room temperature at a dilution of 1/100 in medium supplemented with 1% fetal bovine serum. At 24 h after transfection with Ad-b-gal, cells were fixed with 2.00% formaldehyde and 0.05% glutaraldehyde in phosphate-buffered saline, and stained with X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside). The capacity of the cellular repair systems was assayed by counting the positively stained cells under a microscope. The results using irradiated Ad-b-gal were compared with those in cells treated with nonirradiated Ad-b-gal. Using radiation doses in the range of 1000-4000 Gy, dose-response relationships can be established for the Ad-b-gal vector based on the relative survival of the reporter gene expression. This degree of relative survival is an indication of the relative capacity of the host cell for repair of radiation-induced DNA damage. Such high doses of radiation are necessitated by the small genome size of the adenoviral vector compared to a mammalian cell. Calculations indicate that 4000 Gy should induce about 1-2 DSBs/vector particle. The experiments were carried out in triplicate.
